- Home
- AIRS vs PBYI Comparison
AIRS vs PBYI Comparison
Compare AIRS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- PBYI
- Stock Information
- Founded
- AIRS 2012
- PBYI 2010
- Country
- AIRS United States
- PBYI United States
- Employees
- AIRS N/A
- PBYI N/A
- Industry
- AIRS Medical/Nursing Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- PBYI Health Care
- Exchange
- AIRS Nasdaq
- PBYI Nasdaq
- Market Cap
- AIRS 166.3M
- PBYI 167.3M
- IPO Year
- AIRS 2021
- PBYI N/A
- Fundamental
- Price
- AIRS $4.90
- PBYI $3.31
- Analyst Decision
- AIRS Hold
- PBYI Strong Buy
- Analyst Count
- AIRS 3
- PBYI 1
- Target Price
- AIRS $3.75
- PBYI $7.00
- AVG Volume (30 Days)
- AIRS 698.1K
- PBYI 354.2K
- Earning Date
- AIRS 08-08-2025
- PBYI 07-31-2025
- Dividend Yield
- AIRS N/A
- PBYI N/A
- EPS Growth
- AIRS N/A
- PBYI 143.51
- EPS
- AIRS N/A
- PBYI 0.77
- Revenue
- AIRS $172,101,000.00
- PBYI $232,709,000.00
- Revenue This Year
- AIRS N/A
- PBYI N/A
- Revenue Next Year
- AIRS $4.90
- PBYI N/A
- P/E Ratio
- AIRS N/A
- PBYI $4.34
- Revenue Growth
- AIRS N/A
- PBYI 2.68
- 52 Week Low
- AIRS $1.53
- PBYI $2.23
- 52 Week High
- AIRS $9.20
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- AIRS 58.37
- PBYI 47.57
- Support Level
- AIRS $4.62
- PBYI $3.34
- Resistance Level
- AIRS $5.28
- PBYI $3.39
- Average True Range (ATR)
- AIRS 0.48
- PBYI 0.16
- MACD
- AIRS -0.07
- PBYI -0.04
- Stochastic Oscillator
- AIRS 57.25
- PBYI 19.05
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.